Advertisement

Epitope Mapping of Tetanus Toxin by Monoclonal Antibodies: Implication for Immunotherapy and Vaccine Design

  • Somayeh Ghotloo
  • Forough Golsaz-Shirazi
  • Mohammad Mehdi Amiri
  • Mahmood Jeddi-Tehrani
  • Fazel ShokriEmail author
Review Article
  • 17 Downloads

Abstract

Tetanus as a life-threatening disease is characterized by muscle spasm. The disease is caused by the neurotoxin of Clostridium tetani. Active form of tetanus neurotoxin is composed of the light chain (fragment A) and the heavy chain. Fragment A is a zinc metalloprotease, which cleaves the neuronal soluble N-ethylmaleimide-sensitive attachment receptor (SNARE) protein, leading to the blockade of inhibitory neurotransmitter release and subsequent generalized muscular spasm. Two functional domains of the heavy chain are fragment C, which is required for neuronal cell binding of the toxin and subsequent endocytosis into the vesicles, and fragment B, which is important for fragment A translocation across the vesicular membrane into the neuronal cytosol. Currently, polyclonal immunoglobulins against tetanus neurotoxin obtained from human plasma of hyper-immunized donors are utilized for passive immunotherapy of tetanus; however, these preparations have many disadvantages including high lot-to-lot heterogeneity, possibility of transmitting microbial agents, and the adverse reactions to the other proteins in the plasma. Neutralizing anti-tetanus neurotoxin monoclonal antibodies (MAbs) lack these drawbacks and could be considered as a suitable alternative for passive immunotherapy of tetanus. In this review, we provide an overview of the literature discussing epitope mapping of the published neutralizing MAbs against tetanus toxin.

Keywords

Epitope mapping Tetanus toxin Monoclonal antibody Immunotherapy Vaccine design 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

  1. Ahnert-higer G, Bizinni B, Goretzki K, Muller H, Volckers C, Habbermann E (1983) Monoclonal antibodies against tetanus toxin and toxoid. Med Microbiol Immunol 172:123–135CrossRefGoogle Scholar
  2. Arunachalam B, Ghosh S, Talwar GP, Raghupathy R (1992) A single human monoclonal antibody that confers total protection from tetanus. Hybridoma 11:165–179CrossRefGoogle Scholar
  3. Ashton AC, Li Y, Doussau F, Weller U, Dougan G, Poulain B, Dolly JO (1995) Tetanus toxin inhibits neuroexocytosis even when its Zn21-dependent protease activity is removed. J Biol Chem 270:31386–31390CrossRefGoogle Scholar
  4. Blum FC, Tepp WH, Johnson EA, Barbieri JT (2014) Multiple domains of tetanus toxin direct entry into primary neurons. Traffic 15:1057–1065CrossRefGoogle Scholar
  5. Chen C, Fu Z, Kim JJ, Barbieri JT, Baldwin MR (2009) Gangliosides as high affinity receptors for tetanus neurotoxin. J Biol Chem 284:26569–26577CrossRefGoogle Scholar
  6. Diamant E, Torgeman A, Ozeri E, Zichel R (2015) Monoclonal antibody combinations that present synergistic neutralizing activity: a platform for next-generation anti-toxin drugs. Toxins (Basel) 7:1854–1881CrossRefGoogle Scholar
  7. Council of Europe (2010) European pharmacopoeia. Council Of Europe : European Directorate for the Quality of Medicines and Healthcare, StrasbourgGoogle Scholar
  8. Fairweather NF, Lyness VA, Maskell DJ (1987) Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immul 55:2541–2545Google Scholar
  9. Figueiredo D, Turcotte C, Frankel G, Li Y, Dolly O, Wilkin G, Marriott D, Fairweather N, Dougan G (1995) Characterization of recombinant tetanus toxin derivatives suitable for vaccine development. Infect Immun 63:3218–32121Google Scholar
  10. Fitzsimmons SP, Clark KC, Wilkerson R, Shapiro MA (2000) Inhibition of tetanus toxin fragment C binding to ganglioside G(T1b) by monoclonal antibodies recognizing different epitopes. Vaccine 19:114–121CrossRefGoogle Scholar
  11. Gustafsson B, Whitmore E, Tiru M (1993) Neutralization of tetanus toxin by human monoclonal antibodies directed against tetanus toxin fragment C. Hybridoma 12:699–708CrossRefGoogle Scholar
  12. Helting TB, Zwisler O, Wiegandt H (1977) Structure of tetanus toxin. J Biol Chem 252:194–198Google Scholar
  13. Kamei M, Hashizume S, Sugimoto N, Ozutsumi K, Matsuda M (1990) Establishment of stable mouse/human-human hybrid cell lines producing large amounts of anti-tetanus human monoclonal antibodies with high neutralizing activity. Eur J Epidemiol 6:386–397CrossRefGoogle Scholar
  14. Lalli G, Herreros J, Osborne SL, Montecucco C, Rossetto O, Schiavo G (1999) Functional characterisation of tetanus and botulinum neurotoxins binding domains. J Cell Sci 112:2715–27124Google Scholar
  15. Lang AB, Cryz SJ Jr, Schurch U, Ganss MT, Bruderer U (1993) Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J Immunol 151:466–472Google Scholar
  16. Lin CS, Habig WH, Hardegree MC (1985) Antibodies against the light chain of tetanus toxin in human sera. Infect Immul 49:111–115Google Scholar
  17. Lukic I, Marinkovic E, Filipovic A, Krnjaja O, Kosanovic D, Inic-Kanada A, Stojanovic M (2015) Key protection factors against tetanus: anti-tetanus toxin antibody affinity and its ability to prevent tetanus toxin - ganglioside interaction. Toxicon 103:135–144CrossRefGoogle Scholar
  18. Luo P, Qin L, Mao X, Chen L, Yu S, Li Q, Liu W, Zhang W, Gu J, Zou Q (2012) Identification of a novel linear epitope in tetanus toxin recognized by a protective monoclonal antibody: implications for vaccine design. Vaccine 30:6449–6455CrossRefGoogle Scholar
  19. Matsuda M, Kamei M, Sugimoto N, Ma Y, Hashizume S (1992) Characteristics of toxin-neutralization by anti-tetanus human monoclonal antibodies directed against the three functional domains [A], [B] and [C] of the tetanus toxin molecule and a reliable method for evaluating the protective effects of monoclonal antibodies. Eur J Epidemiol 8:1–8CrossRefGoogle Scholar
  20. Pellizzari R, Rossetto O, Schiavo G, Montecucco C (1999) Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond Ser B Biol Sci 354:259–268CrossRefGoogle Scholar
  21. Petrusic V, Zivkovic I, Stojanovic M, Stojicevic I, Marinkovic E, Dimitrijevic L (2012) Production, characterization and applications of a tetanus toxin specific monoclonal antibody T-62. Acta Histochem 114:480–486CrossRefGoogle Scholar
  22. Pincus SH, Das A, Song K, Maresh GA, Corti M, Berry J (2014) Role of Fc in antibody-mediated protection from ricin toxin. Toxins (Basel) 6:1512–1525CrossRefGoogle Scholar
  23. Scott N, Qazi O, Wright MJ, Fairweather NF, Deonarain MP (2010) Characterisation of a panel of anti-tetanus toxin single-chain Fvs reveals cooperative binding. Mol Immunol 47:1931–1941CrossRefGoogle Scholar
  24. Scrivner D, Kristof S, Rodey G (1987) Human T4 + T-lymphocyte clones specific for the B fragment of tetanus toxin. Hum Immunol 19:245–254CrossRefGoogle Scholar
  25. Sheppard AJ, Cussell D, Hughes M (1984) Production and characterization of monoclonal antibodies to tetanus toxin. Infect Immun 43:710–714Google Scholar
  26. Thwaites CL, Beeching NJ, Newton CR (2015) Maternal and neonatal tetanus. Lancet 385:362–370CrossRefGoogle Scholar
  27. Volk WA, Bizzini B, Snyder RM, Bernhard E, Wagner RR (1984) Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun 45:604–609Google Scholar
  28. Yousefi M, Khosravi-Eghbal R, Reza Mahmoudi A, Jeddi-Tehrani M, Rabbani H, Shokri F (2014a) Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies. Hum Vaccin Immunother 10:344–351CrossRefGoogle Scholar
  29. Yousefi M, Tahmasebi F, Younesi V, Razavi A, Khoshnoodi J, Bayat AA, Abbasi E, Rabbani H, Jeddi-tehrani M, Shokri F (2014b) Characterization of neutralizing monoclonal antibodies directed against tetanus toxin fragment C. J Immunotoxicol 11:28–34CrossRefGoogle Scholar
  30. Yousefi M, Younesi V, Bayat AA, Jadidi-Niaragh F, Abbasi E, Razavi A, Khosravi-eghbal R, Asgarian-omaran H, Shokri F (2016) Comparative human and mouse antibody responses against tetanus toxin at clonal level. J Immunotoxicol 13:243–248CrossRefGoogle Scholar
  31. Yu YZ, Gong ZW, Ma Y, Zhang SM, Zhu HQ, Wang WB, Du Y, Wang S, Yu WY, Sun ZW (2011) Co-expression of tetanus toxin fragment C in Escherichia coli with thioredoxin and its evaluation as an effective subunit vaccine candidate. Vaccine 29:5978–5985CrossRefGoogle Scholar
  32. Ziegler-Heitbrock HW, Reiter C, Trenkmann J, Futterer A, Riethmuller G (1986) Protection of mice against tetanus toxin by combination of two human monoclonal antibodies recognizing distinct epitopes on the toxin molecule. Hybridoma 5:21–31CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Immunology, School of Public HealthTehran University of Medical SciencesTehranIran
  2. 2.Department of Laboratory Medicine, School of Allied Medical SciencesKashan University of Medical SciencesKashanIran
  3. 3.Monoclonal Antibody Research CenterAvicenna Research Institute, ACECRTehranIran

Personalised recommendations